Smruthi Organics FY26 Results: Net Profit ₹342.57 Lakh, AGM on Aug 10
Smruthi Organics reported FY26 net profit of ₹342.57 lakh on revenue of ₹10,196.71 lakh, with Q4 net profit at ₹106.70 lakh. The company confirmed July 31, 2026 as the record date for a ₹1.50 per share (15%) dividend, subject to shareholder approval at the 37th AGM on August 10, 2026. The board also appointed Ms. Smruthi Purushotham Eaga as Whole Time Director effective June 1, 2026.

*this image is generated using AI for illustrative purposes only.
Smruthi Organics Limited announced its audited standalone financial results for the year ended March 31, 2026, following a board meeting held on May 13, 2026. The company reported a net profit of ₹342.57 lakh for the fiscal year, compared to ₹356.29 lakh in the previous year. Revenue from operations for FY26 stood at ₹10,196.71 lakh, a decrease from ₹12,600.79 lakh in the prior year. The board also disclosed key corporate calendar dates, including the scheduling of the 37th Annual General Meeting (AGM) and the record date for dividend payment. Subsequently, the company formally intimated BSE Limited on May 14, 2026, confirming Friday, July 31, 2026 as the record date for determining members eligible to receive the dividend for FY 2025-26.
Financial Performance
For the fourth quarter ended March 31, 2026, the company recorded a net profit of ₹106.70 lakh on revenue from operations of ₹2,908.87 lakh. Total expenses for the quarter were reported at ₹2,735.67 lakh. The board approved the audited financial results, which received an unmodified opinion from the statutory auditors, M/s Gokhale & Sathe, Chartered Accountants.
Key Financial Metrics
The following table outlines the standalone financial performance for the year and quarter ended March 31, 2026:
| Particulars: | Year Ended 31-03-2026 (₹ in Lakhs) | Year Ended 31-03-2025 (₹ in Lakhs) | Quarter Ended 31-03-2026 (₹ in Lakhs) |
|---|---|---|---|
| Revenue from Operations (Net): | 10,196.71 | 12,600.79 | 2,908.87 |
| Total Expenses: | 9,696.38 | 12,119.67 | 2,735.67 |
| Profit Before Tax: | 466.43 | 490.00 | 173.85 |
| Net Profit for the Period: | 342.57 | 356.29 | 106.70 |
| Earnings Per Share (Basic): | 2.99 | 3.11 | 0.93 |
Dividend Declaration and AGM Details
The board of directors has recommended a dividend of ₹1.50 per equity share (15%) for the financial year ended March 31, 2026, payable on 1,14,46,290 equity shares of ₹10 each. This dividend is subject to the approval of shareholders at the 37th Annual General Meeting, which has been fixed for Monday, August 10, 2026, to be held through Video Conferencing (VC) or other Audio-Visual Means (OAVM) in accordance with relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. The dividend, if declared at the AGM, shall be paid within the prescribed statutory timelines.
Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Register of Members and Share Transfer Books of the company will remain closed from Saturday, August 1, 2026 to Monday, August 10, 2026 (both days inclusive) for the purpose of the AGM and payment of dividend. The record date for dividend eligibility has been set as Friday, July 31, 2026. The dividend will be paid to shareholders whose names appear as beneficial owners in the records of National Securities Depository Limited and Central Depository Services (India) Limited, or as members in the Register of Members, as at the end of business hours on July 31, 2026.
Corporate Calendar
The following table summarises the key dates announced by the board:
| Event: | Details |
|---|---|
| 37th AGM Date: | Monday, August 10, 2026 |
| AGM Mode: | Video Conferencing / Audio-Visual Means |
| Book Closure Period: | August 1, 2026 to August 10, 2026 (both days inclusive) |
| Record Date (Dividend): | Friday, July 31, 2026 |
| Dividend Recommended: | ₹1.50 per equity share of ₹10 each (15%) |
| Subject To: | Shareholder approval at ensuing AGM |
Management Changes
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the board disclosed the appointment of Ms. Smruthi Purushotham Eaga (DIN: 09268342) as a Whole Time Director (Executive) for a period of three years, effective from June 1, 2026. This represents a change in designation from her previous role as Non-Executive (Non-Independent) Director of the company. The appointment is based on the recommendation of the Nomination and Remuneration Committee and is subject to shareholder approval at the upcoming AGM.
Ms. Smruthi Purushotham Eaga holds an MS Degree in Pharmacy from the USA and has previously worked with the company as a Business Development Executive. She has also worked in different companies in the US for about 5 years. Since FY 2021-2022, she has handled International Marketing activities of the company, particularly in Central and South American Markets, involving identification, interaction, development, and monitoring of customers for the company's existing products. She is the daughter of Mr. Purushotham Eaga, Chairman and Managing Director, and sister of Mr. Swapnil Eaga, Joint Managing Director & CFO.
Appointment Details
The following table summarises the key details of the management change:
| Parameter: | Details |
|---|---|
| Name: | Ms. Smruthi Purushotham Eaga |
| DIN: | 09268342 |
| Previous Designation: | Non-Executive (Non-Independent) Director |
| New Designation: | Whole Time Director (Executive) |
| Effective Date: | June 1, 2026 |
| Term: | 3 years |
| Subject To: | Shareholder approval at ensuing AGM |
Historical Stock Returns for Smruthi Organics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.95% | -4.37% | +4.37% | -12.21% | -1.84% | -50.42% |
What strategic initiatives is Smruthi Organics planning to reverse the ~19% revenue decline in FY26 and return to growth in FY27?
How might Ms. Smruthi Purushotham Eaga's appointment as Whole Time Director accelerate the company's expansion into Central and South American markets?
Given the increasing concentration of family members in key executive roles, how could institutional investors and minority shareholders respond to governance concerns at the upcoming AGM?
































